Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The […]
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| Cat. #: | 151855 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Microbiology |
| Application: | ELISA ; IF ; Fn ; WB |
| Target: | Human Respiratory Syncytial (RS) virus Fusion glycoprotein |
| Reactivity: | Virus |
| Clone: | 11-5-G9 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | VP7, F |
|---|---|
| Product description: | Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kDa. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | Human Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract illness and is the chief cause of hospitalization for respiratory tract illness in young children.The glycoprotein F is located on the surface of viral envelope, its function is to induce fusion of viral envelope with host-cell envelope resulting in syncytium formation. The glycoprotein F (also named VP70, F0 or fusion protein) consists of two components: F1 (also named VPG48) and F2 (also named VGP26) held together by disulphide bonds. The reported molecular weight of the VGP26 component varies between 20 to 26 kDa. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1mg/ml |
| Storage buffer: | DulbeccoĂÂs media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM plus 60 ml Fetal Bovine Serum plus 3ml L-Glutamine). |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Gimenez et al. 1986. Journal General Virology, 67: 863-870. PMID: 3517224 Gimenez et al. 1984. Journal General Virology, 65: 963-71. PMID: 6202832 Gimenez et al. 1987. Journal General Virology, 68: 1267-75. PMID: 3572364 Gimenez et al. 1996. Clinical and Diagnostic Laboratory Immunology, 3: 280-86, PMID: 8705669 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.